Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
ABVX Stock Chart & Stats
$117.67
-$0.09(-1.29%)
At close: 4:00 PM EST
$117.67
-$0.09(-1.29%)
Day’s Range― - ―
52-Week Range$4.77 - $148.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)1.45M
Market Cap
$9.06B
Enterprise Value$7.79B
Total Cash (Recent Filing)$60.95M
Total Debt (Recent Filing)$84.57M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Mar 23, 2026EPS Estimate
-1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding79,072,624
10 Day Avg. Volume798,858
30 Day Avg. Volume1,450,453
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.98
Price to Sales (P/S)41.30
P/FCF Ratio-2.88
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue827.82
Enterprise Value/Gross Profit827.82
Enterprise Value/Ebitda-34.56
Forecast
1Y Price Target
$150.71Price Target Upside28.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionOnce-daily oral dosing combined with a novel mechanism and encouraging efficacy positions obefazimod to gain adoption across multiple treatment lines in an expanding inflammatory bowel disease market.
Independent Safety ReviewIndependent Data Safety Monitoring Board reported no new safety concerns in a late-stage maintenance study of obefazimod, supporting tolerability and reducing regulatory uncertainty.
Regulatory PathwaySuccessful pivotal maintenance data would support a regulatory submission and potential approval, strengthening commercialization prospects for obefazimod.
Bears Say
Cardiac Safety ConcernElevated miR-124 levels associated with obefazimod may be linked to cardiac dysfunction and heart failure risk, increasing long-term safety scrutiny versus well-characterized alternatives.
Financing RiskHigh cash burn relative to available resources could necessitate additional fundraising, risking shareholder dilution and potential delays to development programs.
Pancreatic Safety SignalInduction trial findings of elevated pancreatic enzymes raise concerns about potential pancreatitis risk, which could complicate regulatory review and clinician acceptance.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $9.06B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Mar 23, 2026 which is in 41 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Dec 15, 2025. The company reported -$2.472 earnings per share for the quarter, missing the consensus estimate of -$0.786 by -$1.686.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -1.53.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 79,072,624 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$2.472 in its last earnings report, missing expectations of -$0.786. Following the earnings report the stock price went down -5.877%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Company Description
Abivax SA Sponsored ADR
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$150.71
▲(28.08% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
―
Insiders
5.00% Mutual Funds
0.04% Other Institutional Investors
91.23% Public Companies and Individual Investors